JP2010510210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510210A5 JP2010510210A5 JP2009537124A JP2009537124A JP2010510210A5 JP 2010510210 A5 JP2010510210 A5 JP 2010510210A5 JP 2009537124 A JP2009537124 A JP 2009537124A JP 2009537124 A JP2009537124 A JP 2009537124A JP 2010510210 A5 JP2010510210 A5 JP 2010510210A5
- Authority
- JP
- Japan
- Prior art keywords
- ethynyl
- hydroxyl
- compound
- oxime
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 12
- 150000002148 esters Chemical class 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 8
- 229910052731 fluorine Inorganic materials 0.000 claims 8
- 239000011737 fluorine Substances 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 150000002923 oximes Chemical class 0.000 claims 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 7
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 7
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 7
- -1 3α-fluoro Chemical compound 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- RSRDWHPVTMQUGZ-QGVNFLHTSA-N 1-[(5s,8r,9s,10s,13s,14s,17s)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 RSRDWHPVTMQUGZ-QGVNFLHTSA-N 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- RSRDWHPVTMQUGZ-QYYVTAPASA-N 1-[(5r,8r,9s,10s,13s,14s,17s)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 RSRDWHPVTMQUGZ-QYYVTAPASA-N 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- XPZHAZFQUFNMAU-HKQXQEGQSA-N n-[(5r,8r,9s,10s,13s,14s)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-ylidene]hydroxylamine Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=NO)[C@@H]4[C@@H]3CC[C@H]21 XPZHAZFQUFNMAU-HKQXQEGQSA-N 0.000 claims 3
- YYRQQDKUSIWHRJ-QYYVTAPASA-N n-[1-[(5r,8r,9s,10s,13s,14s,17s)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethylidene]hydroxylamine Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=NO)C)[C@@]2(C)CC1 YYRQQDKUSIWHRJ-QYYVTAPASA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- YJDYCULVYZDESB-HQEMIIEJSA-N (8r,9s,10s,13s,14s)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC21 YJDYCULVYZDESB-HQEMIIEJSA-N 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 150000002576 ketones Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86065806P | 2006-11-21 | 2006-11-21 | |
| US60/860,658 | 2006-11-21 | ||
| PCT/SE2007/050876 WO2008063128A1 (en) | 2006-11-21 | 2007-11-20 | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013097487A Division JP5657052B2 (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097485A Division JP2013173781A (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097486A Division JP5918170B2 (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510210A JP2010510210A (ja) | 2010-04-02 |
| JP2010510210A5 true JP2010510210A5 (OSRAM) | 2012-07-12 |
| JP5386362B2 JP5386362B2 (ja) | 2014-01-15 |
Family
ID=39429970
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537124A Expired - Fee Related JP5386362B2 (ja) | 2006-11-21 | 2007-11-20 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097487A Expired - Fee Related JP5657052B2 (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097485A Pending JP2013173781A (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097486A Active JP5918170B2 (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2015047791A Pending JP2015147774A (ja) | 2006-11-21 | 2015-03-11 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013097487A Expired - Fee Related JP5657052B2 (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097485A Pending JP2013173781A (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097486A Active JP5918170B2 (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2015047791A Pending JP2015147774A (ja) | 2006-11-21 | 2015-03-11 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (9) | US8580983B2 (OSRAM) |
| EP (4) | EP2711371B1 (OSRAM) |
| JP (5) | JP5386362B2 (OSRAM) |
| AU (1) | AU2007322423C1 (OSRAM) |
| BR (2) | BR122013033954B8 (OSRAM) |
| CA (2) | CA2833976C (OSRAM) |
| DK (3) | DK2097437T3 (OSRAM) |
| ES (3) | ES2607852T3 (OSRAM) |
| HU (3) | HUE033037T2 (OSRAM) |
| IN (1) | IN2014DN02014A (OSRAM) |
| MX (1) | MX2009005335A (OSRAM) |
| PL (3) | PL2711371T3 (OSRAM) |
| PT (1) | PT2097437E (OSRAM) |
| RU (1) | RU2458065C2 (OSRAM) |
| SI (1) | SI2097437T1 (OSRAM) |
| WO (1) | WO2008063128A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2711371T3 (pl) * | 2006-11-21 | 2018-06-29 | Asarina Pharma Ab | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun |
| CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| WO2011087441A1 (en) | 2010-01-14 | 2011-07-21 | Umecrine Mood Ab | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| EP2566482A1 (en) * | 2010-05-07 | 2013-03-13 | Institut National de la Santé et de la Recherche Médicale | Progesterone receptor antagonists and uses thereof |
| JP6205362B2 (ja) | 2011-09-08 | 2017-09-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| HRP20170503T1 (hr) * | 2012-11-28 | 2017-06-16 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | 3-(4'-supstituirani)-benzil-eter derivati pregnenolona |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| ME03351B (me) * | 2014-01-29 | 2019-10-20 | Umecrine Cognition Ab | Steroidno jedinjenje za upotrebu u lečenju hepatične encefalopatije |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| SMT202000276T1 (it) * | 2014-11-27 | 2020-07-08 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| AR103384A1 (es) | 2015-01-12 | 2017-05-03 | Umecrine Cognition Ab | 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA |
| SMT202100226T1 (it) | 2015-07-06 | 2021-05-07 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| SG10202002655VA (en) | 2015-07-06 | 2020-05-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| DE102015120587A1 (de) | 2015-11-26 | 2017-06-01 | Brandenburgische Technische Universität Cottbus-Senftenberg | Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden |
| PL3436022T3 (pl) | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
| CN119350419A (zh) | 2016-10-18 | 2025-01-24 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| ES3038660T3 (en) | 2016-10-18 | 2025-10-14 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| AU2018218823B2 (en) | 2017-02-10 | 2022-12-22 | Relmada Therapeutics, Inc. | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment |
| WO2018147791A1 (en) | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor |
| KR102771577B1 (ko) | 2017-11-27 | 2025-02-20 | 유메크린 코그니션 에이비 | 3α-에티닐-3β-하이드록시안드로스탄-17-온 옥심의 약학적 제형 |
| RU2020130861A (ru) | 2018-04-05 | 2022-05-05 | Асарина Фарма Апс | Антагонисты гамка для применения в лечении расстройств отмены психоактивного вещества |
| CN116059215B (zh) | 2019-01-08 | 2025-10-03 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
| CN112457362B (zh) * | 2019-09-06 | 2023-09-19 | 上海青东生物科技有限公司 | 一种卤代四环三萜衍生物及其制备与应用 |
| EP4079307A1 (en) | 2021-04-20 | 2022-10-26 | Umecrine Cognition AB | New medical use |
| US20240383941A1 (en) | 2021-11-10 | 2024-11-21 | Umecrine Ab | 3-alpha substituted 3-beta-hydroxy-17-oximated androstane compound for modulation of the alpha-3 subtype of the gabaa receptor |
| WO2023083979A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
| WO2023083980A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | Steroid as a modulator of gabaa receptor |
| EP4389129A1 (en) * | 2022-12-22 | 2024-06-26 | Umecrine Cognition AB | 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia |
| WO2025252724A1 (en) | 2024-06-04 | 2025-12-11 | Umecrine Cognition Ab | Novel pharmaceutical formulation of golexanolone |
| WO2025252725A1 (en) | 2024-06-04 | 2025-12-11 | Umecrine Cognition Ab | Novel pharmaceutical formulation of golexanolone |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1463755A (fr) * | 1960-01-26 | 1966-07-22 | Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation | |
| US3152121A (en) * | 1962-03-16 | 1964-10-06 | Upjohn Co | 20-ketals of 3-hydroxy-5 beta-pregnan-20-one |
| CH491889A (de) * | 1966-10-22 | 1970-06-15 | Richter Gedeon Vegyeszet | Verfahren zur Herstellung von Steroiden |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) * | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5234603A (en) | 1991-06-04 | 1993-08-10 | Analytical Development Corporation | Methods employing a zirconium salt for use in wastewater treatment |
| DE69435286D1 (de) * | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| EP0752860B1 (en) | 1994-02-14 | 2000-08-23 | Euro-Celtique S.A. | Androstanes and pregnanes for allosteric modulation of gaba receptor |
| CA2205919A1 (en) * | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| DE69634039T2 (de) * | 1995-06-06 | 2005-12-08 | Euro-Celtique S.A. | Steroidderivate der Androstan- und der Pregnanreihe |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| ATE307592T1 (de) | 1998-03-11 | 2005-11-15 | Torbjoern Backstroem | Epiallopregnanolon zur behandlung von krankheiten des cns |
| AU3467699A (en) | 1998-04-14 | 1999-11-01 | Pharmadigm, Inc. | Method for reducing central nervous system impairment |
| US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| CZ294278B6 (cs) * | 1999-11-25 | 2004-11-10 | Ústav organické chemie a biochemie AV ČR | Neuroaktivní steroidy a způsob jejich přípravy |
| GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
| GB2363983A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| FR2831441B1 (fr) * | 2001-10-25 | 2003-12-26 | Oreal | Utilisation cosmetique de derives de la dhea |
| EP1310258A1 (en) * | 2001-11-08 | 2003-05-14 | Etienne-Emile Baulieu | Enantiomers of steroids for the enhancement of memory and cognitive function |
| SE0104423D0 (sv) * | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
| JP4914368B2 (ja) * | 2004-11-18 | 2012-04-11 | ウメクライン アーベー | Ｇａｂａ−ステロイド拮抗剤およびｃｎｓ疾患の治療のためのその使用 |
| PL2711371T3 (pl) | 2006-11-21 | 2018-06-29 | Asarina Pharma Ab | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun |
| EP2566482A1 (en) | 2010-05-07 | 2013-03-13 | Institut National de la Santé et de la Recherche Médicale | Progesterone receptor antagonists and uses thereof |
-
2007
- 2007-11-20 PL PL13198584T patent/PL2711371T3/pl unknown
- 2007-11-20 BR BR122013033954A patent/BR122013033954B8/pt not_active IP Right Cessation
- 2007-11-20 RU RU2009107537/04A patent/RU2458065C2/ru active
- 2007-11-20 PT PT78354594T patent/PT2097437E/pt unknown
- 2007-11-20 JP JP2009537124A patent/JP5386362B2/ja not_active Expired - Fee Related
- 2007-11-20 ES ES14154304.1T patent/ES2607852T3/es active Active
- 2007-11-20 DK DK07835459.4T patent/DK2097437T3/en active
- 2007-11-20 HU HUE14154304A patent/HUE033037T2/hu unknown
- 2007-11-20 ES ES07835459.4T patent/ES2543841T3/es active Active
- 2007-11-20 PL PL07835459T patent/PL2097437T3/pl unknown
- 2007-11-20 CA CA2833976A patent/CA2833976C/en active Active
- 2007-11-20 ES ES13198584.8T patent/ES2662500T3/es active Active
- 2007-11-20 CA CA2664126A patent/CA2664126C/en active Active
- 2007-11-20 EP EP13198584.8A patent/EP2711371B1/en not_active Not-in-force
- 2007-11-20 EP EP13198608.5A patent/EP2711372A1/en not_active Withdrawn
- 2007-11-20 EP EP07835459.4A patent/EP2097437B1/en active Active
- 2007-11-20 PL PL14154304T patent/PL2792681T3/pl unknown
- 2007-11-20 BR BRPI0718945A patent/BRPI0718945B8/pt active IP Right Grant
- 2007-11-20 DK DK13198584.8T patent/DK2711371T3/en active
- 2007-11-20 HU HUE07835459A patent/HUE026961T2/en unknown
- 2007-11-20 EP EP14154304.1A patent/EP2792681B1/en not_active Not-in-force
- 2007-11-20 DK DK14154304.1T patent/DK2792681T3/en active
- 2007-11-20 US US11/943,555 patent/US8580983B2/en not_active Expired - Fee Related
- 2007-11-20 HU HUE13198584A patent/HUE036410T2/hu unknown
- 2007-11-20 SI SI200731681T patent/SI2097437T1/sl unknown
- 2007-11-20 AU AU2007322423A patent/AU2007322423C1/en active Active
- 2007-11-20 WO PCT/SE2007/050876 patent/WO2008063128A1/en not_active Ceased
- 2007-11-20 MX MX2009005335A patent/MX2009005335A/es active IP Right Grant
- 2007-11-20 IN IN2014DEN2014 patent/IN2014DN02014A/en unknown
-
2012
- 2012-12-17 US US13/716,794 patent/US20130102578A1/en not_active Abandoned
- 2012-12-17 US US13/716,984 patent/US20130102579A1/en not_active Abandoned
-
2013
- 2013-03-07 US US13/787,924 patent/US8853190B2/en active Active
- 2013-03-07 US US13/788,006 patent/US20140011792A1/en not_active Abandoned
- 2013-03-07 US US13/788,074 patent/US20140011793A1/en not_active Abandoned
- 2013-03-22 US US13/848,782 patent/US9200028B2/en active Active
- 2013-05-07 JP JP2013097487A patent/JP5657052B2/ja not_active Expired - Fee Related
- 2013-05-07 JP JP2013097485A patent/JP2013173781A/ja active Pending
- 2013-05-07 JP JP2013097486A patent/JP5918170B2/ja active Active
-
2015
- 2015-03-11 JP JP2015047791A patent/JP2015147774A/ja active Pending
- 2015-07-10 US US14/796,301 patent/US20150315231A1/en not_active Abandoned
- 2015-11-19 US US14/945,575 patent/US20160272670A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510210A5 (OSRAM) | ||
| EP0097572B1 (fr) | Nouveaux 19-nor stéroides substitués en 11 et éventuellement en 2,leur préparation, leur application comme médicaments, les compositions les renfermant et les nouveaux intermédiaires obtenus | |
| KR0161975B1 (ko) | 11베타-치환 프로게스테론 유사체 | |
| CN1129602C (zh) | 11－(取代的苯基)－雌－4,9－二烯衍生物 | |
| RU2009107537A (ru) | Новые стероидные соединения, обладающие повышенной растворимостью в воде и устойчивостью к метаболизму, и способы их приготовления | |
| US9388210B2 (en) | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| EP2456781B1 (de) | 17-hydroxy-17-pentafluorethyl-estra-4,9 (10)-dien-11-acyloxyalkylenphenyl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten | |
| JP6254289B2 (ja) | エステトロールの製造プロセス | |
| DE69326805T2 (de) | 17-Spiromethylensteroide | |
| FR2598421A1 (fr) | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant | |
| US20150259376A1 (en) | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| TW518339B (en) | 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives | |
| US10202413B2 (en) | Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for GABA type-A receptors | |
| JP5261481B2 (ja) | １７−アセトキシ−１１β−［４−（ジメチルアミノ）−フェニル］−２１−メトキシ−１９−ノルプレグナ−４，９−ジエン−３，２０−ジオンの合成のための工業的方法およびプロセスのキーとなる中間体 | |
| PT85891B (pt) | Processo para a preparacao de 9-alfa-hidroxi-esteroides e dos respectivos derivados 9(11)-deidro bem como de composicoes farmaceuticas que os contem | |
| WO1983003099A1 (fr) | 3-ceto-delta 4,9-19-norsteroides | |
| DE102009034366A1 (de) | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten | |
| JP2008512426A5 (OSRAM) | ||
| FI56389C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 18-metyl-4,15-estradienderivat | |
| KR20160051693A (ko) | 이미다졸릴 프로게스테론 길항제 | |
| JPH0383998A (ja) | Ｃ１７‐２０リアーゼ阻害剤として有用な４‐置換１７β‐（シクロプロピルアミノ）アンドロスト‐５‐エン‐３β‐オール及び関連化合物類 | |
| JPH02268194A (ja) | アミド又はカルバメート官能基を含有する炭素鎖を１１β位置に有する新規の１９―ノルステロイド、それらの製造方法及びこの方法の中間体、それらの薬剤としての使用並びにそれらを含有する製薬組成物 | |
| CN1131158A (zh) | 具有17-螺亚甲基内酯或邻位羟基内醚基的甾族化合物， | |
| EP1599493B1 (de) | Antitumor wirksame 2-substituierte estra-1,3,5(10)-trien-3-yl sulfamate | |
| JPS59106500A (ja) | 新規６α―メチルコルチコイド及びその製法 |